**Demographic characteristics and clinical outcomes in patients from Latin America versus the rest of the world: a TIOSPIR® post-hoc analysis**

Antonio Anzueto, Peter M.A. Calverley, Achim Mueller, Norbert Metzdorf, Michaela Haensel, José R. Jardim, Emilio Pizzichini, Horacio Giraldo, Alejandra Ramirez-Venegas, Eduardo R. Giugno

Online data supplement

**Table S1**

Serious adverse events by region (on-treatment analysis)

|  |  |  |  |
| --- | --- | --- | --- |
| **Serious adverse events, *n* (incidence rate/100 patient-years)** | **Latin America(*n*=1000)** | **RoW(*n*=16 116)** | **Latin Americavs RoWIRR (95% CI)** |
| Patients with SAEs | 269 (15.7) | 5356 (19.2) | 0.82 (0.72–0.92) |
| Cardiac disorders | 32 (1.7) | 804 (2.4) | 0.68 (0.48–0.97) |
| Gastrointestinal disorders | 26 (1.4) | 414 (1.3) | 1.08 (0.73–1.61) |
| General disorders and administration site conditions | 17 (0.9) | 301 (0.9) | 0.98 (0.60–1.59) |
| Hepatobiliary disorders | 9 (0.5) | 93 (0.3) | 1.68 (0.85–3.34) |
| Infections and infestations | 99 (5.3) | 1395 (4.3) | 1.22 (1.00–1.50) |
| Injury, poisoning, and procedural complications  | 11 (0.6) | 295 (0.9) | 0.65 (0.35–1.18) |
| Neoplasms: benign, malignant, and unspecified  | 25 (1.3) | 778 (2.4) | 0.55 (0.37–0.82) |
| Nervous system disorders  | 12 (0.6) | 383 (1.2) | 0.54 (0.30–0.96) |
| Psychiatric disorders  | 2 (0.1) | 70 (0.2) | 0.49 (0.12–2.02) |
| Respiratory, thoracic, and mediastinal disorders COPD  | 138 (7.6)121 (6.6) | 2800 (9.1)2493 (8.1) | 0.83 (0.70–0.99)0.82 (0.69–0.99) |
| Vascular disorders  | 11 (0.6) | 263 (0.8) | 0.72 (0.40–1.32) |

On-treatment analysis (from randomization to drug stop date + 30 days).

CI, confidence interval; COPD, chronic obstructive pulmonary disease; RoW, rest of the world; IRR, incidence rate ratio; SAE, serious adverse event.